Familiar Therapeutics, a Redwood City-based biotechnology company, has launched with a US$5 million seed round to bring modern human medicines to dogs and cats. The financing was led by Pioneer Fund, Icehouse Ventures, and BreakTHRU, a syndicate of animal health industry leaders and veterinarians. Angel investors including a Robinhood co-founder and a founding member of OpenAI and Y Combinator also participated.
Addressing the Veterinary Treatment Gap
Dogs and cats develop many of the same diseases as people, but very little modern medical progress has reached them. The FDA approves fewer than 10 new drugs for companion animals each year, compared with more than 50 for people. For many serious conditions, veterinarians still rely on human medicines used off-label without species-specific dosing or safety data.
Familiar was built to close this gap by licensing veterinary rights to drugs with years of human research behind them. The company leads the clinical development, manufacturing, and FDA review work needed for approval in dogs and cats. This approach aims to bring disease-modifying medicines to pets faster than the seven to ten years a new animal drug typically takes.
Founders and Early Momentum
Familiar was founded by serial entrepreneurs Elizabeth Iorns, PhD, and Dan Knox, MBA, who previously co-founded Science Exchange and led it through its acquisition in 2024. The Y Combinator-backed research and development outsourcing platform is used by the world's largest pharmaceutical companies. The gap became personal for Iorns in 2020, when her French Bulldog, Lily, was diagnosed with a terminal brain tumor.
Iorns, a cancer biologist, identified a checkpoint inhibitor tested in pet dogs with brain tumors but not developed for veterinary use. She and Knox licensed that therapy and ran a registrational canine osteosarcoma study that recently met its endpoint. In its first five months, Familiar built a pipeline of four lead programs and nine earlier-stage programs, signed multiple licensing agreements, opened two INAD files with the FDA Center for Veterinary Medicine, and filed one provisional patent.
Lead Program and Pipeline
Familiar's most advanced program, FAM-010, targets hemangiosarcoma, one of the most aggressive cancers in dogs and a disease with no FDA-approved treatment. With surgery alone, median survival is under two months. The company is working toward making FAM-010 the first FDA-approved treatment for hemangiosarcoma in dogs, starting this fall with a pilot study at the University of Illinois College of Veterinary Medicine led by Timothy M. Fan, DVM, PhD.
Other lead programs target intervertebral disc disease, a common cause of back pain and paralysis in dogs, breathing disorders in flat-faced breeds, and immune-mediated diseases. Every program is designed for full FDA approval, and where a program qualifies, Familiar may also seek conditional approval. The seed funding will move its lead programs into clinical studies and advance the rest of its pipeline.
Partnerships and Industry Support
Chief Operating Officer Dan Knox said the evidence generated in pets can also inform and de-risk the biopharma partners' human programs. Partners keep their human rights and share in veterinary sales, creating a faster return on research they have already paid for. This collaborative structure has helped the company sign partners quickly.
Familiar's team includes senior animal health drug developers who have contributed to more than 30 FDA approvals at companies including Zoetis, Elanco, and Bayer Animal Health. The company also has a 12-member Scientific Advisory Board of veterinary specialists and researchers. Robbie Paul, CEO of Icehouse Ventures, said Iorns and Knox are two of New Zealand's most accomplished founders and that pet owners now expect the same standard of care for their animals.
Familiar Therapeutics is positioning itself to bring therapeutic advances to dogs and cats faster than traditional animal drug development allows. With a US$5 million seed round, a growing pipeline, and partnerships in place, the company aims to deliver FDA-approved treatments for serious pet diseases. Its first clinical effort in canine hemangiosarcoma could provide a long-needed option where no approved therapy exists.